ZOVIRAX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
ZOVIRAX by GSK is α-herpesviruses [see ] . Approved for recurrent herpes labialis (cold sores) in immunocompetent adults, adolescents 12 years of age, older. First approved in 1982.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOVIRAX is an injectable antiviral small molecule approved in 1982 for the treatment of serious viral infections, primarily herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. The drug works by inhibiting viral DNA polymerase, preventing viral replication in infected cells. It is administered intravenously and remains a foundational therapy in acute viral infection management.
LOE Approaching
As LOE approaches, the brand team is likely consolidating focus on cost-efficiency and retention strategies rather than growth initiatives.
Mechanism of Action
α-herpesviruses [see ] .
Worked on ZOVIRAX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.